WIN $150 GIFT VOUCHERS: ALADDIN'S GOLD

Close Notification

Your cart does not contain any items

$318.95

Hardback

Not in-store but you can order this
How long will it take?

QTY:

English
Academic Press Inc
01 September 2024
Breaking Tolerance to Unresponsiveness to Immunotherapy by Natural Killer Cells presents chapters by leaders in translational natural killer cell research and bridges the gap between clinical need and basic science by presenting state-of-the-art knowledge on innate immunity and the challenges associated with translating it to practical adoptive immunotherapies. New approaches, such as the genetic engineering of NK cells and their combination with checkpoint blockade therapies are discussed among other potential interventions to improve natural killer cell functionality against targets. In addition, challenges, such as the difficulty in genetically modifying NK cells or a poor understanding of their effect on checkpoint inhibition are included.

The book is a key reference and go-to resource for researchers and clinicians who want to understand the current limitations associated with bringing natural killer cell-based immunotherapies to the clinic.
Edited by:  
Imprint:   Academic Press Inc
Country of Publication:   United States
Dimensions:   Height: 235mm,  Width: 191mm, 
ISBN:   9780128206270
ISBN 10:   0128206276
Series:   Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
Pages:   200
Publication Date:  
Audience:   Professional and scholarly ,  Undergraduate
Format:   Hardback
Publisher's Status:   Active

As faculty in the College of Pharmacy at Purdue University, Dr. Matosevic leads an active, externally-funded research program in immunotherapy with natural killer cells. He has made important contributions to the field of NK cell immunotherapy and continues to study their reprogramming in the microenvironment of tumors and how this can be overcome to advance their use in the clinic. Dr. Matosevic has extensive experience in cell-based therapies with NK cells. Apart from a prolific research output, he has led important initiatives in cell therapy, aimed at standardizing cell-based therapy development and manufacturing with ISO and USP, as well as having organized and co-chaired a workshop at the National Institute of Standards and Technology with an international audience of academic and industrial stakeholders. He has acted on the Communications Committee of the International Society for Cellular Therapy and continue to organize and chair academic meetings on natural killer cell-based therapies.

See Also